Glycation

Definition

Glycation (non-enzymatic glycosylation) is the spontaneous, irreversible covalent attachment of a reducing sugar (most commonly glucose) to free amino groups — primarily the ε-amine of lysine residues and the α-amine of protein N-termini — without enzymatic catalysis.

Not to be confused with N-glycosylation, which is enzymatic and occurs on Asn-X-Ser/Thr sequons.

Mechanism (Maillard reaction)

1. Schiff base formation — glucose aldehyde condenses with free amine → unstable aldimine (+162.053 Da)
2. Amadori rearrangement — rearranges to stable ketoamine (fructosamine) — this is the measured product in most MS studies (+162.053 Da net)
3. Advanced Glycation End-products (AGEs) — further reactions over weeks/months produce cross-links, fluorescent adducts, and pentosidine — irreversible and accumulate with glycemic exposure

Rate depends on: glucose concentration × time × lysine accessibility × protein half-life.

Mass spectrometry signature

• Δmass: +162.053 Da (hexose, most commonly glucose)
• Affected residues: Lys (ε-amine), protein N-terminus (α-amine)
• Common HSA sites: Lys4, Lys12, Lys51, Lys199, Lys281, Lys439, Lys525, Lys545
• Detection: intact protein MS (top-down) or modified peptide MS (bottom-up after trypsin digestion)
• Challenge: multiple sites can be simultaneously glycated → combinatorial complexity in top-down MS

Biological significance

• Glycation at active sites or binding pockets alters protein function
• On HSA: glycation at fatty acid binding sites reduces drug-carrying capacity
• Reflects cumulative glucose exposure over the protein’s lifetime (for HSA: ~20 days)
• Driver of diabetic complications through AGE accumulation in long-lived proteins (collagen, crystallin)

Clinical relevance

• HbA1c (glycated hemoglobin) — gold standard for glycemic monitoring (reflects ~3 months)
• Glycated HSA (fructosamine) — reflects shorter-term glycemic control (~2–3 weeks); relevant when HbA1c is unreliable (hemolytic anemia, hemoglobin variants)
• In liver disease: glycated HSA may serve as independent biomarker of hepatic dysfunction, since liver synthesizes HSA — both concentration and glycation pattern may change
• ⚠️ Non-linear relationship between plasma glucose and site-specific glycation on HSA — different sites have different reactivity

Affected proteins in our research

• HSA — primary target (ALBOM study)
• Transferrin — less studied, N-glycosylation is enzymatic but glycation also occurs
• Fibrinogen, Haptoglobin — known glycation targets

In chronic liver disease (ALBOM data — el-balkhi-2025)

Glycation of HSA shows a biphasic pattern across CLD stages:

• Controls → compensated cirrhosis (F4_A): HSA+GLYC concentration rises (escalating glycative stress)
• F4_A → F4_B/C (decompensation): HSA+GLYC concentration falls (substrate depletion as native HSA collapses)

The ratio HSA+GLYC/Native correctly captures this and monotonically increases:

• Best single discriminator for F4_B (Sens 85%, Spec 100% vs controls)
• Uniquely capable of discriminating controls from F2 (earliest fibrosis marker among individual isoforms)
• Sensitivity 70%, Specificity 99% for F4_C vs controls

The doubly-glycated cysteinylated form (HSA+CYS+2GLYC, Δmass +443 Da) is a monotonically increasing end-stage marker — near-zero in controls, detectable only in cirrhotic patients and increasing with Child-Pugh severity (F4_A: 0.12 g/L → F4_C: 0.2 g/L).

Key interpretive note: in CLD, do not interpret absolute glycated isoform concentration in isolation — always use the ratio to native HSA to account for the collapse of the substrate pool in decompensated disease.

Key references

• el-balkhi-2025 — quantitative data on HSA glycation across CLD stages; cross-platform LC-HR-MS